Frontiers in Immunology · 2021 · 14 citations · 42 references
Life SciencesGeneticsImmunologyCancer GeneticsHuman GeneticsImmunogeneticsCancer GenomicsGenetic Risk AssessmentLung CancerTumor AntigensTumor-associated AntigensCancer Risk AssociationGenetic Predisposition To CancerHla Class I MoleculesHla Risk AllelesMolecular Risk MarkersSingle Nucleotide Polymorphism Association StudiesSingle-nucleotide PolymorphismsSmoking-related Genetic Risk
Lung cancer is strongly associated with cigarette smoking; nevertheless some never-smokers develop cancer. Immune eradication of cancer cells is dependent on polymorphisms of HLA class I molecules and antigen-processing machinery (APM) components. We have already published highly significant associations of single nucleotide polymorphisms (SNPs) of the ERAP1 gene with non-small cell lung cancer (NSCLC) in Chinese, but not in Polish populations. However, the smoking status of participants was not known in the previous study. Here, we compared the distribution of APM polymorphic variants in larger cohorts of Polish patients with NSCLC and controls, stratified according to their smoking status. We found significant but opposite associations in never-smokers and in smokers of all tested SNPs ( rs26653, rs2287987, rs30187 , and rs27044 ) but one ( rs26618 ) in ERAP1 . No significant associations were seen in other genes. Haplotype analysis indicated that the distribution of many ERAP1/2 haplotypes is opposite, depending on smoking status. Additionally, haplotypic combination of low activity ERAP1 and the lack of an active form of ERAP2 seems to favor the disease in never-smokers. We also revealed interesting associations of some APM polymorphisms with: age at diagnosis ( ERAP1 rs26653 ), disease stage ( ERAP1 rs27044 , PSMB9 rs17587 ), overall survival ( ERAP1 rs30187 ), and response to chemotherapy ( ERAP1 rs27044 ). The results presented here may suggest the important role for ERAP1 in the anti-cancer response, which is different in smokers versus never-smokers, depending to some extent on the presence of ERAP2, and affecting NSCLC clinical course.
42
Patti A. Groome, Vanessa Bolejack, John J. Crowley et al. · Journal of Thoracic Oncology · 2007 · 619 citations · Full text
The revised TNM staging system for lung cancer.
Ramón Rami–Porta, John J. Crowley, Peter Goldstraw · PubMed · 2009 · 438 citations